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Pre-exposure prophylaxisTransmission of drug-resistant HIV has been widely documented. We generated tenofovir (TFV)- and
emtricitabine (FTC)-resistant SHIV162P3 mutants that can be used to investigate the transmission efﬁciency
of drug-resistant viruses and their impact on the efﬁcacy of pre-exposure prophylaxis. Both SHIV162p3M184V
and SHIV162p3K65R replicated in vitro at high titers. Drug resistance proﬁles were similar to those seen in HIV.
Virus infectivity to virion particle ratios were 4- and 10-fold lower in SHIV162p3M184V and SHIV162p3K65R,
compared to a concurrently generated WT SHIV162p3, respectively. Mucosal transmissibility studies using a
repeat low-dose macaque model of rectal and vaginal transmission showed that both mutants were able to
efﬁciently infect macaques only after the dose was increased to adjust for ﬁtness reductions due to K65R and
M184V. Our results in limited number of macaques suggest that the reduction in ﬁtness due to M184V and
K65R decreases virus transmissibility, and identify in vitro infectivity parameters that associate with mucosal
transmissibility.rt are those of the authors and
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Oral administration of antiretroviral drugs before HIV exposure
(pre-exposure prophylaxis or PrEP) is a promising intervention to
protect high-risk HIV-1 negative people from becoming infected
(Cohen et al., 2007; Garcia-Lerma et al., 2010b; Grant et al., 2005).
Drug candidates for PrEP have been mostly selected from currently
approved drugs for treatment of HIV-1-infected individuals. Among
the available drugs, the reverse transcriptase (RT) inhibitors tenofovir
disoproxil fumarate (TDF; an oral prodrug of tenofovir (TFV)), and
emtricitabine (FTC) havemany favorable characteristics for PrEP. Both
drugs are very potent and well tolerated, and the active diphosphate
metabolites have a long intracellular half life in peripheral blood
mononuclear cells (PBMCs). Consequently, all human PrEP clinical
trials are evaluating TDF or TFV either alone or in combination with
FTC (Garcia-Lerma et al., 2010b). The results from these trials are
widely anticipated because if PrEP is found to be safe and effective it
may represent an important biomedical intervention to prevent HIV
infection. A recently completed trial with daily Truvada among
HIV-seronegativemen or transgenderwomenwho have sexwithmenhas shown a 44% reduction in the incidence of HIV-1, giving the ﬁrst
indication that oral PrEP may potentially provide an additive effect to
current proven HIV prevention measures (Grant et al., 2010).
TDF, FTC, and the closely related drug lamivudine (3TC) are
important components of ﬁrst line therapy and have been extensively
used over the past few years. Resistance to FTC in HIV and SIV is
primarily mediated by a Met to Val mutation at position 184 of the RT
(Schinazi et al., 1993; Schuurman et al., 1995; van Rompay et al.,
2002; Wainberg et al., 1996; Wainberg et al., 1995). The M184V
mutation reduces the susceptibility of HIV and SIV for FTC by N
100-fold and confers hyper-susceptibility to TFV (Miller, 2004). K65R
is the primary mutation associated with HIV and SIV resistance to TFV
and also confers low-level resistance to other NRTIs including FTC
(Miller, 2004; van Rompay et al., 1996; Wainberg et al., 1999). K65R
can also be selected with abacavir, didanosine, and stavudine.
In areas with widespread access to antiretroviral drugs, drug-
resistant viruses are frequently transmitted (Geretti, 2007). It is
therefore essential to understand if circulating viruses that are
resistant to FTC or tenofovir compromise the efﬁcacy of PrEP with
TDF or Truvada. The impact of these mutants on PrEP efﬁcacy in
humans can be assessed by studying acute infections in PrEP
breakthrough infections and determining the frequency of drug-
resistant HIV that initiated these infections. However, this type of
analysis is difﬁcult in humans and often not feasible because it
requires sampling early during infection andM184V and K65R tend to
revert and become undetectable due to their high ﬁtness costs (Cane,
2005; Cong et al., 2007; Deval et al., 2004a,b; White et al., 2002). Thus
Fig. 1. Susceptibility of SHIV162P3M184V and SHIV162P3K65R to tenofovir (TFV) and
emtricitabine (FTC). Values denote the percentage of protection seen in TZMBl cells at
increasing concentrations of TFV (A) or FTC (B). Each experiment was done in triplicate.
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transmitted resistance and the accurate assessment of the impact of
drug-resistant viruses on PrEP efﬁcacy.
Here we report on the generation, characterization, and mucosal
transmissibility in macaques of two simian/human immunodeﬁciency
virus (SHIV) mutants resistant to TFV and FTC that can be used to
model the transmissibility of these viruses and their impact on PrEP
efﬁcacy. We focused on both K65R and M184V to account for the two
most common mutations associated with TFV and FTC resistance
(Shafer and Schapiro, 2008). The SHIV162P3 backgroundwas selected
because this WT isolate has been extensively used to evaluate the
relative efﬁcacy of different PrEP strategies in a well-validated repeat-
low dose rectal or vaginal transmissionmodel (Kim, 2006; Otten et al.,
2005; Subbarao et al., 2006). In this model, daily and intermittent oral
PrEP with FTC, TDF, or Truvada (a combination of FTC and TDF)
prevented or delayed infection in macaques repeatedly exposed
rectally to SHIV162P3 (Garcia-Lerma et al., 2010a; García-Lerma et al.,
2008; Subbarao et al., 2006). A topical 1% TFV gel also protected
pigtails macaques from repeated vaginal SHIV162P3 exposures
(Parikh et al., 2009).
We demonstrate successful rectal and vaginal infectionwith newly
generated SHIV162P3M184V and SHIV162P3K65R stocks in rhesus and
pigtail macaques. We also show that the reduced virus ﬁtness
associated with M184V and K65R required an increase in the virus
inocula thus suggesting that drug-resistant viruses may be less
transmissible. These new viruses are important reagents for under-
standing the clinical signiﬁcance of drug resistance and the potential
impact of drug resistance on the efﬁcacy of PrEP with FTC, TFV, or
Truvada.
Results
Characteristics of drug-resistant SHIV162p3 mutants
The following isolates were expanded in rhesus or pigtail PBMCs:
SHIV162P3WT, SHIV162P3M184V, and SHIV162P3K65R. The N69S and
I118V mutations were introduced into SHIV162P3K65R since single
K65Rmutants grew very poorly (data not shown). N69S and I118V are
commonly seen inwild type SIV, do not increase resistance to TFV, and
improve ﬁtness of SIV mutants containing K65R in vivo (Myers et al.,
1991; van Rompay et al., 1996). Table 1 shows the characteristics of all
the virus stocks generated in PBMCs from rhesus or pigtail macaques.
Titers of SHIV RNA and p27 antigen seen in virus stocks generated
in rhesus PBMC were high and comparable in the three isolates. In
contrast, infectious virus titers were 4- and 16-fold lower in
SHIV162P3M184V and HIV162P3K65R relative to SHIV162P3WT, respec-
tively. As a measure of replicative capacity we calculated the ratios
between infectious virus titers in PBMCs (TCID50) and virion particles
expressed as RNA or p27 content. This ratio is frequently used to
evaluate the impact of resistance mutations on virus ﬁtness (García-
Lerma et al., 2000; Martinez-Picado et al., 1999). Virus infectivity/RNA
particle ratios in SHIV162P3M184V and HIV162P3K65R were 4-fold and
9-fold lower than the ratio seen in SHIV162p3WT, respectively. Similar
reductions were seen by measuring the relationship between TCID50Table 1
Characteristics of SHIV162-p3 stocks generated in rhesus and pigtail PBMCs.
RNA (copies/ml) p27 antigen (pg/ml) Infectio
Rhesus stocks
SHIV162P3wt 2.57×109 49,577 10,160
SHIV162P3M184V 2.62×109 28,022 2,540
SHIV162P3K65R 1.44×109 48,783 630
Pigtail stocks
SHIV162P3wt 1.24×109 87,598 210,291
SHIV162P3K65R 1.58×109 207,934 16,127
a Mean titer from two separate experiments done in triplicate.and p27 antigen; ratios were 2- and 20-fold lower than in wild type
SHIV162P3. These results demonstrate that, as in HIV, the M184V and
K65R mutations in SIV RT reduce virus replicative capacity (Table 1)
(Cong et al., 2007; van Rompay et al., 2002).
The HIV162P3K65R mutant was also expanded in PBMCs from
pigtail macaques. Table 1 shows the characteristic of the pigtail virus
stock collected at 21 days of culture. Similar to that seen with the
rhesus K65R stock, levels of RNA and p27 antigen were high and
comparable to those seen in SHIV162p3WT. In contrast, infections
virus titers and virus infectivity/virion particle ratios were about
10- to 20-fold lower in HIV162P3K65R relative to SHIV162p3WT,
respectively (Table 1).
We next evaluated the impact of M184V and K65R on FTC and TFV
susceptibility. As expected, M184V conferred high level (N100-fold)
resistance to FTC and hyper-susceptibility (0.3-fold) to TFV. Similarly,
the K65Rmutation conferred resistance to both FTC (27-fold) and TFV
(18-fold) (Fig. 1). The reductions in drug susceptibility were also
evident using a biochemical RT activity assay. Fig. 2 shows thatM184V
conferred 113-fold resistance to FTC-TP and 0.8-fold resistance to
TFV-DP. Similarly, the K65R mutation reduced the susceptibility for
both FTC-TP and TFV-DP (20- and 9.8-fold, respectively). Thus, the
drug resistance proﬁle of SHIV162P3M184V and HIV162P3K65R was
similar to that seen in HIV-1.
Rectal infection of rhesus macaques with SHIV162P3M184V
We used an established repeat low-dose rhesus macaque model
of rectal virus transmission to evaluate if SHIV162P3M184V couldus titer (TCID50/ml)a Infectivity/RNA (×106) Infectivity/p27 antigen
3.96 0.20
0.97 (4.1) 0.09 (2)
0.44 (9) 0.01 (20)
169.6 2.4
10.2 (16.6) 0.08 (30)
Fig. 2. Susceptibility of SHIV162P3M184V and SHIV162P3K65R reverse transcriptase (RT)
to tenofovir-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP). Values denote the
inhibition of RT activity observed at increasing concentrations of TFV-DP (A) or FTC-TP
(B). Each experiment was done in triplicate.
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macaques exposed to 10 TCID50 of the parenteral SHIV162P3 wild
type (WT) are generally infected after a median of three rectal
challenges (Garcia-Lerma et al., 2010a; García-Lerma et al., 2008; KimFig. 3. Rectal transmissibility of SHIV162P3M184V. Rhesus macaques were exposed
rectally once a week to 10 TCID50 (A) or 40 TCID50 (B) of SHIV162P3M184V. Infection was
monitored by serology and PCR ampliﬁcation of viral RNA or DNA sequences. Only one
macaque became infected during six exposures to 10 TCID50. All three macques
exposed to 40 TCID50 were infected. The cross symbol denotes euthanasia in one
animal. Green arrow indicates seroconversion.et al., 2006; Subbarao et al., 2006). We ﬁrst explored if the same virus
dose would be sufﬁcient to initiate a systemic M184V infection. Fig. 3A
shows that of the two rhesus macaques exposed to 10 TCID50, only one
was infected after six challenges suggesting a reduced transmissibility
of SHIV162P3M184V relative to the WT SHIV162P3 isolate. To explore if
virus transmissibility could be increased at higher doses, we exposed
three additional rhesus macaques to 40 TCID40. A 4-fold increase in the
dose was selected to account for the 4-fold reduction in virus
infectivity/virion RNA ratio seen in SHIV162P3M184V relative to the
WT SHIV162P3 (Table 1). Fig. 3B shows that at 40 TCID50, all three
macaques were infected after a median of three exposures; one animal
was infected at challenge 2, one at challenge 3, and one at challenge 7.
Average peak virus load was 6.1 log10 vRNA copies/ml (range, 5.2–7.3
log10 copies/ml) and was signiﬁcantly lower than that seen in 22
historical controls (7.1 log10 RNA copies/ml, range=5.3–8.9, p=0.04,
Wilcoxon test) infected with the parental WT SHIV162P3 (Garcia-
Lerma et al., 2010a). Seroconversion was observed in all animals
within 2–4 weeks after the ﬁrst detectable vRNA; proviral DNA was
consistently detected within 1–2 weeks (Fig. 3B). Sequence analysis of
viruses from plasma collected 3–16 weeks after infection conﬁrmed
the presence of the M184V mutation in viruses from all three
macaques.
Vaginal infection of macaques with SHIV162P3K65R
The transmissibility of SHIV162P3K65R was evaluated in a pigtail
macaque model of vaginal infection consisting of 2 weekly virus
exposures (Otten et al., 2005; Parikh et al., 2009). Despite introducing
the N69S and I118V mutations in SHIV162P3K65R to improve virus
ﬁtness, virus infectivity to virion particle ratios was still 17-fold lower
than those seen in SHIV162P3WT (Table 1). We therefore increased
the SHIV162P3K65R virus dose 17 times (170 TCID50) for vaginal
exposures. At this virus dose, two of the three pigtail macaques
became infectedwith detectable vRNA after eight and nine challenges.
Virus loads in these two animals peaked at 3.9 and 5.2 log10 RNA
copies/ml and remained detectable during a total follow-up period of
40 days after infection. Both animals seroconverted and had detect-
able proviral DNA (Fig. 4). Sequence analysis conﬁrmed maintenance
of K65R in viruses from both macaques at day 28 post infection.
Discussion
Several PrEP human clinical trials with oral or topically administered
antiretroviral drugs are now at varying stages of completion (Garcia-
Lerma et al., 2010b). Most studies are using TFV-containing products,
either alone or in combinationwith FTC. One trial (VOICE) is comparing
oral TDF or TDF/FTC to topical PrEPwith a TFV vaginal gel. These studies
will provide valuable information including safety, efﬁcacy for themajorFig. 4. Vaginal transmissibility of SHIV162P3K65R. Pigtail macaques were exposed
vaginally twice a week to 170 TCID50 of SHIV162P3K65R. Two of the three macaques
became infected after eight exposures (28 days). Green arrow indicates seroconver-
sion. Peak viremias might have been missed since specimens could not be collected
between days 28 and 35.
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drug dosing (Garcia-Lerma et al., 2010b). The recent ﬁndings that a 1%
TFV gel provided protection (38%) against vaginal HIV transmission and
thatdaily oral Truvadaprovidedprotection (44%) fromHIVamongMSM
are the ﬁrst indications that oral and topical antiretroviral PrEPmay be a
feasible strategy for preventing sexual HIV transmission (Abdool Karim
et al., 2010; Grant et al., 2010).
Since drug-resistant viruses are circulating in areaswithwidespread
access to antiretroviral drugs it is essential to understand the potential
impact of FTC and TFV-resistant viruses on the efﬁcacy of PrEP with
Truvadaor TDF.However, itwill bedifﬁcult to address thesequestions in
acutely infected people since transmitted resistance mutations tend to
rapidly revert after infection and become undetectable (Cong et al.,
2007). Here we report on the generation and characterization of
SHIV162P3 mutants resistant to FTC and TFV that can be used to model
in macaques, the transmissibility of these viruses and their potential
impact on PrEP efﬁcacy.We showefﬁcient systemic infectionwith these
viruses by both the rectal and vaginal routes. In the case ofM184V, peak
virus loads were consistently lower than those seen in macaques
infected rectally with the parental wild type SHIV162P3, a ﬁnding that
may be explained by the impact of M184V on replicative ﬁtness. It will
be important to further conﬁrm these observations with larger number
of animals exposed to SHIV162P3M184V.
Although drug-resistant viruses including mutants containing
M184V and K65R are known to be transmissible, attempts to evaluate
their transmission efﬁciency relative to WT viruses have thus far been
limited. Earlier attempts to evaluate transmission efﬁciencies of drug-
resistant viruses were mainly focused on the comparison of the
frequencies of resistance mutations between treated and untreated
populations as surrogates of the transmitter and recipient groups,
respectively (Leigh Brown et al., 2003; Murray, 2003). While these
studies have suggested diverse transmission efﬁciencies, they are
biased by the frequent reversion of resistance mutations in untreated
persons due to a ﬁtness cost (Geretti, 2007).We show inmacaques that
mucosal transmissibility of the M184V mutant is lower than WT virus.
However, transmissibility may be enhanced to WT levels by increasing
the dose in a proportional manner to the ﬁtness cost deﬁned on the
basis of infectivity to virion RNA ratios. Our results provide the ﬁrst
direct evidence suggesting that drug-resistant viruses with demon-
strable reductions in replicative ﬁtness are less transmissible than WT
viruses and identify in vitro infectivity parameters that associate with
transmissibility.
Vaginal infection with SHIV162P3K65R was only seen after eight
and nine virus exposures compared to a median of 4.5 exposures seen
in earlier studies done with larger number of animals exposed to the
parental SHIV162P3 virus (Parikh et al., 2009). The differences in time
for infection may reﬂect sample size, differences between the original
SHIV162P3 virus and our clonal SHIV162P3K65R, and other factors that
are known to inﬂuence susceptibility to vaginal infection such as stage
of the menstrual cycle and thinning of the vaginal epithelium (Ajay
Vishwanathan et al., 2010; Wira and Fahey, 2008). In contrast, such
differences in time for infection were not observed with rectal
exposures to SHIV162P3M184V. After adjusting the infectious dose of
SHIV162P3M184V based on the wild type SHIV162P3 clone, all three
macaques were infected after three challenges as previously seen in
animals exposed rectally to the parenteral SHIV162P3 isolate (Garcia-
Lerma et al., 2010a). These observations suggest that infectivity
adjustments with SHIV162P3M184V were sufﬁcient to recapitulate the
rectal transmission efﬁciency of the parental SHIV162P3.
In generating ourM184V and K65Rmutantswe elected to introduce
two nucleotide changes to minimize risks for mutational reversion
during early infection, as it is known that transmitted drug-resistant
viruses mutants may rapidly revert toWT in vivo (Brenner et al., 2002;
Cane, 2005). Our experimental approach also has the advantage of
allowing us to understand the impact that M184V or K65Rmay have on
acute infection. It will be interesting to see if the low virus ﬁtness due toM184V and the associated blunted viremias seen in our macaques may
impact early virus diversiﬁcation.
In summary, we generated new SHIV162P3 stocks resistant to FTC
and TFV and demonstrate successful vaginal and rectal transmission
in macaques. Our results with SHIV162P3M184V suggest that the
reduction in ﬁtness due to M184V may associate with decreased
virus transmissibility. These newly generated viruses are useful tools
that may help to understand the clinical and pathogenic impact of
drug resistance and the potential impact of circulating resistance on
the efﬁcacy of oral and topical PrEP with tenofovir, FTC/3TC, and
Truvada.
Material and methods
Generation of SHIV162P3 mutants resistant to TFV and FTC
Plasmids pVP1 andpSHIVp3gp160were kindly providedbyDr. Cecilia
Cheng-Mayer from the Aaron Diamond AIDS Research Center. Plasmid
pVP1 contains the 5′ portion of SIVmac239 from the 5′ long terminal
repeat to a Sph I restriction site at nucleotide 6707, and plasmid
pSHIVp3gp160 contains the gp160 region of SHIV162P3 (Harouse et al.,
2001;Harouse et al., 1999;Hsuet al., 2005; Luciwet al., 1995). TheM184V
and K65R mutations associated with FTC and TFV resistance were
introduced in pVP1 by site-directed mutagenesis (QuikChange II XL,
Stratagene). Although one single nucleotide change is sufﬁcient to
generate M184V and K65R, we introduced two nucleotide changes
(AAA→CGA for K65R and ATG→GTT for M184V) to minimize reversion
of mutations in vitro and in vivo. Reverse transcriptase mutations N69S
and I118V were also introduced in pVP1K65R to compensate for the
reduced ﬁtness conferred by K65R (van Rompay et al., 1996). The
following forward mutagenic primers were used (mutations are under-
lined): (SIV184V2F; 5′CCTTAGTCCAGTATGTTGATG ACATCTTAATAGC3′)
forM184V, (SIV65R-69S1F; 5′GCTATAAAGCGAAAGGATAAGAGCAAATG-
GAGAATGCTGATAG3′) for K65R and N69S, and (SIVI118V1F;5′GTGATG-
CATATTTCTCCGTACCTCTAGATGAAGAATTTAGG) for I118V.
Infectious viruses SHIV162P3WT, SHIV162P3M184V, and SHIV162P3K65R
were generated in human embryonic kidney (HEK-293T) cells after
ligation of plasmids pVP1, pVP1M184V, or pVP1K65R with plasmid
pSHIVp3gp160 (Rapid DNA ligase, Roche). Cells were transfected using
the Lipofectamine 2000 kit (Invitrogen). Viruses were expanded in
CD8-depleted rhesus or pigtail macaque PBMCs. Supernatants were
collected at the end of the culture, pre-cleared by centrifugation at
1200 rpm for 7 min, andﬁltered through a 0.45-μm-pore-sizemembrane.
Virus stocks expanded in rhesus PBMCswere collected at day 14 andvirus
stocks expanded in pigtail PBMCswere collected at day 21based on visual
inspection of the cultures. However, all three viruses (SHIV162P3WT,
SHIV162P3M184V, and SHIV162P3K65R) were collected the same day for
each source of PBMCs. All virus stockswere stored in liquid nitrogen until
use.
Titration of virus stocks
The 50% tissue culture infective dose (TCID50) of each virus stockwas
determined by endpoint dilution as described (Japour et al., 1993).
Brieﬂy, rhesus or pigtail macaque PBMCs (200,000 cells/well) were
added to 96-well ﬂat-bottomed microtiter culture plates (Costar) and
exposed to serial dilutions of each virus isolate. Cells were examined at
day 7 for p27 antigen production (ZeptoMetrix Corporation). Infectious
virus titers were determined using the Spearman–Karber method (19).
Quantiﬁcation of SHIV RNA in virus stocks and plasma
SHIV RNA was quantiﬁed using a real-time RT-PCR assay previously
described (Subbarao et al., 2006). This assay format has a sensitivity of
50RNA copies/ml. RNAwas extracted from culture supernatant (100 μl)
or plasma (1 ml) using the QIAamp Viral RNA kit (Qiagen). Prior to RNA
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known amount of virus particles (3×105) from an HIV-1 CM240 virus
stock was added to each sample. Reverse transcription and PCR
ampliﬁcation of SHIV (gag) and HIV-1 (env) was performed using
primers speciﬁc for SIVmac239 and HIV-1 CM240, respectively
(Subbarao et al., 2006). HIV-1 CM240 was obtained from the National
Institutes of Health (NIH) AIDS Research and Reference Reagent
Program.Drug susceptibility
The susceptibility of SHIV162P3M184V and SHIV162P3K65R to TFV and
FTC was evaluated both in culture using TZM-bl cells and biochemically
by an enzymatic RT activity assay. The TZM-bl assay evaluates drug
susceptibility based on reductions in Tat-regulated Luc reporter gene
expression (Wei et al., 2002). Brieﬂy, cells (3×104) were exposed
to ~107 virus particles (measured by genomic RNA levels) in triplicate
both in the absence and presence of serial dilutions of FTC or TFV (from
100 to 0.0013 μM). The concentration of drug required to inhibit 50%
luciferase activity was calculated after 2 days in culture.
Enzymatic susceptibility of SHIV RT for TFV-DP and FTC-TP was
determined using Amp-RT, a PCR-based RT activity assay (García-Lerma
et al., 2001). Amp-RT detects RT activity by using a known non-retroviral
heteropolymeric RNA template derived from the encephalomyocarditis
virus (EMCV) genome and a complementary EMCV-speciﬁc DNA primer
(García-Lerma and Heneine, 1999). Testing conditions included triplicate
RT reactions done with the RT activity contained in approximately 4000
particles of each virus isolate (as measured by genomic RNA levels). RT
reactionsweredone in the absence or in thepresence of TFV-DPor FTC-TP
(from 0.005 to 50 uM). The concentration of each dNTP in the RT reaction
was variable depending on the nucleoside analog tested. A concentration
of 5 μM dCTP or 5 μM dATP was used for reactions containing FTC-TP or
TFV-DP, respectively. The other three dNTPs were used at 20 uM each
(García-Lerma et al., 2001). The RT-generated EMCV cDNA was detected
by real-time PCR ampliﬁcation.Sequence analysis
Sequence analysis of SIV RT (551 bp; amino acids 52–234)was done
using an RT-nested PCR method previously described (Subbarao et al.,
2006). Env sequences (1570 bp; nucleotides 230–2030 of HIV−1 env)
were also generated by RT-nested PCR as described (Hsu et al., 2005).
PCR products were sequenced using an ABI 3130×Genetic Analyzer.
The Vector NTI program (Version 10) was used to analyze the data and
to determine deduced amino acid sequences.Rectal and vaginal infections in macaques
Infectivity of SHIV162P3M184V and SHIV162P3K65R was evaluated
using a repeated exposure macaque model of rectal or vaginal
transmission (Otten et al., 2005; Subbarao et al., 2006). Macaques
were exposed rectally once a week (rhesus) or vaginally twice a week
(pigtail) to variable TCID50 doses. Virus exposures were done by non-
traumatic inoculation of 1 mL of SHIVSF162P3 into the rectal or vaginal
vault via a sterile gastric feeding tube of adjusted length (Otten et al.,
2005). Macaques were anesthetized using standard doses of ketamine
hydrochloride. Anesthetizedmacaques remained recumbent for at least
15 min after each inoculation. Virus exposures were stopped when a
macaque became SHIV RNA positive. Virus-speciﬁc serologic responses
(IgG and IgM) were measured using a synthetic-peptide EIA (BioRad,
Genetic Systems HIV-1/HIV-2, Redmond, WA) assay. The Institutional
Animal Care and Use Committee (IACUC) of the Centers for Disease
Control and Prevention (CDC) approved this study.Acknowledgments
WethankDr.KatherinePaul for servingas theattendingveterinarian
for this animal studyprotocol andDr. Cecilia Cheng-Mayer for providing
us with plasmids pVP1 and pSHIVp3gp160.
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